Sugi Predict

Sugi Predict / Targets / GTPBP10

GTPBP10

GTP-binding protein 10 · A4D1E9 · GTPBP10 on Sugi Atlas →

21 patent compounds predicted against GTPBP10, 17 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL21943538 SCHEMBL21943538 0.59 1/20
SCHEMBL21943762 SCHEMBL21943762 0.57 1/20
SCHEMBL21944043 SCHEMBL21944043 0.55 1/20
SCHEMBL21943004 SCHEMBL21943004 0.55 1/20
SCHEMBL21942995 SCHEMBL21942995 0.53 1/20
SCHEMBL21943411 SCHEMBL21943411 0.53 1/20
SCHEMBL14042267 SCHEMBL14042267 0.52 1/20
SCHEMBL21943429 SCHEMBL21943429 0.52 1/20
SCHEMBL22066328 SCHEMBL22066328 0.51 1/20
SCHEMBL21943540 SCHEMBL21943540 0.49 1/20
SCHEMBL21943537 SCHEMBL21943537 0.45 1/20
SCHEMBL24016281 SCHEMBL24016281 0.44 1/20
SCHEMBL24532074 SCHEMBL24532074 0.42 1/20
SCHEMBL1454562 SCHEMBL1454562 0.42 1/20
SCHEMBL17612956 SCHEMBL17612956 0.42 1/20
SCHEMBL12399198 SCHEMBL12399198 0.42 1/20
SCHEMBL29911712 SCHEMBL29911712 0.40 1/20

Clinical trials — most relevant to GTPBP10 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients PHASE1/PHASE2COMPLETED
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) PHASE2COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer PHASE1COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer PHASE1COMPLETED
Gait in Rare Diseases nanCOMPLETED
Study of the Pathophysiological Mechanisms Involved in Bleeding Events nanCOMPLETED
Role of Polymorphisms in the IL-1 Gene Cluster nanCOMPLETED
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients nanCOMPLETED
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease nanUNKNOWN
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
Gene Analysis of Parkinson's Disease nanCOMPLETED
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH) nanCOMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
Stress and Treatment Response in Puerto Rican Children With Asthma nanCOMPLETED
Mapping Novel Disease Genes for Dilated Cardiomyopathy nanCOMPLETED
Child Development and Genetic Biomarkers(II): Gene Verification and Data Integration nanUNKNOWN
Relationship Between Genes Important in Blood Pressure Regulation and Blood Pressure Therapy in Hypertension nanCOMPLETED
Consortium On Risk for Early-onset Parkinson's Disease (CORE PD) nanCOMPLETED
iPSC Neurons From Adult Survivors of Childhood Cancer Who Have Persistent Vincristine-Induced Neuropathy nanCOMPLETED
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) nanCOMPLETED
Autophagy Bladder Cancer nanUNKNOWN
Investigating the Genetic Basis of Pseudoexfoliation Syndrome, Angle-closure Glaucoma and Primary Open-angle Glaucoma nanRECRUITING
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others nanRECRUITING
Exome Analysis in Hearing Impaired Patients nanUNKNOWN
How Does Your Genetic Make-up (Profile) Influence Your Glaucoma? nanCOMPLETED
New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization nanCOMPLETED
Exploring the Genetics of Neuropathic Pain nanRECRUITING
Signs and Symptoms of Genetic Abnormalities Linked to Inherited Heart Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GTPBP10 binder may also engage these)

ProteinNameSimilarity
Q3MHG6 — 1.000 Q3MHG6 →
Q8K013 — 0.994 Q8K013 →
Q6DHF7 — 0.992 Q6DHF7 →
Q5M8V6 — 0.988 Q5M8V6 →
Q5U528 — 0.987 Q5U528 →
Q5RDW1 — 0.966 Q5RDW1 →
A6QLJ3 — 0.965 A6QLJ3 →
Q9UGC7 — 0.961 Q9UGC7 →
Q9I7M2 — 0.960 Q9I7M2 →
Q29K06 — 0.959 Q29K06 →
O81852 — 0.959 O81852 →
Q8N442 — 0.958 Q8N442 →
Q9H4K7 — 0.958 Q9H4K7 →
Q8C3X4 — 0.957 Q8C3X4 →
Q8R3P0 — 0.957 Q8R3P0 →
PFKP ATP-dependent 6-phosphofructokinase, platelet type 0.956 landscape →
Q8BLR2 — 0.956 Q8BLR2 →
Q0E671 — 0.956 Q0E671 →
E3TDS3 — 0.956 E3TDS3 →
A9M061 — 0.956 A9M061 →
Q8BIP0 — 0.956 Q8BIP0 →
I0IUP3 — 0.956 I0IUP3 →
Q5ZIB9 — 0.955 Q5ZIB9 →
Q6PI48 — 0.955 Q6PI48 →
Q7MW55 — 0.955 Q7MW55 →
B1H116 — 0.955 B1H116 →
UCK2 Uridine-cytidine kinase 2 0.955 landscape →
P06801 — 0.955 P06801 →
A9JTX2 — 0.954 A9JTX2 →
Q5XGR8 — 0.954 Q5XGR8 →